| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.09 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.09 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.1 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |